AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05847959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chinese medicine prescription：XinKang-I
Description: XK-I will be used in intervention group (20 grams of radix astragalus, 20 grams of radix codonopsis, 10 grams of stir-fried semen lepidii, 8 grams of sweet apricot kernel, 10 grams of cassia twig, 15 grams of poria cocos, 10 grams of atractylodes, 5 grams of honey-roasted licorice, 15 grams of radix et rhizoma salviae miltiorrhizae, 10 grams of chuanxiong rhizoma, 5 grams of tangerine peel).Patients will take XK-I once a day, divided into morning and evening administration. The treatment lasted for 8 weeks.
Study NCT06456827 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bite force and Gcf
Description: change in bite force will be measured by bite force measuring device at, T0(at the time of retainer delivery), T1(1 month of retainer delivery), T2(3 months of retainer delivery) and T3 (6 months of retainer delivery) ,T4 (12 months of retainer delivery) time interval.~Changes in the following parameters - changes in change in levels of bone turnover markers CTX and BALP using ELISA at T0(at the time of retainer delivery), T1(1 month of retainer delivery), T2(3 months of retainer delivery) and T3 (6 months of retainer delivery) ,T4 (12 months of retainer delivery) time interval
Study NCT04719624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptos®-Si [0.5-1 mm] (bone grafting surgery)
Description: After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
Study NCT04719624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptos®-Si [1-2 mm] (bone grafting surgery)
Description: After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
Study NCT05315492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Care Consortium (CCC)
Description: The intervention will train community health workers to take an active role in the drug control and addiction service delivery in the community.
Study NCT04719624 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Geistlich Bio-Oss (bone grafting surgery)
Description: After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
Study NCT04719624 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Tooth extraction without bone graft material
Description: After screening and enrollment, subjects will undergo tooth extraction of a single tooth and the socket is filled only by clot. Subject will be followed at 2 weeks, 5 months, and 10 months for healing.
Study NCT04719624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptos® (bone grafting surgery)
Description: After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
Study NCT05368792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complex Carbohydrate (PREcovery)
Description: Each serving of the complex carbohydrate drink is a clear, colorless, 12.5% maltodextrin drink with a citrus taste, prepared by mixing 54 g of powder (50g carbohydrate) with 400mL of cold water. Participants will consume 2 servings of the complex carbohydrate drink the evening before colonoscopy (100g carbohydrate, 800mL fluid), and 1 serving 2 hours before their colonoscopy (50g carbohydrate, 400mL fluid)
Study NCT04334187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based addition treatment
Description: The intervention is comprised of 8 weekly group MBAT sessions. Two weekly groups of about 10 participants each will be conducted. All participants will also have the option to receive nicotine patches, gum, or lozenges for four weeks as part of their time in the study. Participants will complete surveys at enrollment (baseline), immediately after their last MBAT session (around 2 months after enrollment) and one month after completing treatment (3 months post-enrollment). Surveys will assess primary and secondary outcomes and satisfaction with the intervention.
Study NCT06410768 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: multistage shared decision-making program
Description: The multistage shared decision-making program consists of 1) an online patient decision aid; 2) preparatory consult to provide patients with the knowledge and confidence to participate in shared decision-making; and 3) training to improve healthcare professionals' skills for shared decision-making.
Study NCT05944406 — intervention group
Intervention type: OTHER
Intervention: Educational training of ER Nurses
Description: educational intervention was conducted from 2nd to 5th May 2023 with the triage nurses. This intervention comprised of detailed explanations of how the Triage system is accurately used to categorize the patients presenting in the ED and Triage nurses were instructed to refer non-urgent cases to either the Outpatient department or to the Casualty Medical Officer. The results of the first audit were also shared. Additionally, circulars containing instructions regarding accurate usage of MTS were distributed to all triage nurses
Study NCT05907109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remotely monitored parent-mediated hybrid home and clinic based multidisciplinary Early Intervention protocols.
Description: * Parents receive manualized protocols, instructional videos, and toy and material kits to administer EIs at home.~* New modules are provided according to infant age or stage of intervention during the length of brief interventions or 12-months.~* The families will be monitored by clinical researchers weekly. -High risk infants will receive supplemental EI services at the clinic according to developmental needs.~* Infants will receive outcome evaluations within a 42-month follow-up clinic.
Study NCT06268080 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Depth of anesthesia titration using pEEG
Description: Titration of maintenance anesthetic agent (propofol infusion)
Study NCT06268080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depth of anesthesia titration using pEEG
Description: Titration of maintenance anesthetic agent (propofol infusion)
Study NCT04798859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family centered in-home rehabilitation
Description: Goal-oriented individualized intervention targeting brain injury related areas noted as challenging by the child and family
Study NCT04798859 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual follow-up in the municipality
Study NCT05845034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVI + SPEs ablation
Description: electrophysiology substrate mapping is the critical difference between both groups.
Study NCT05845034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI ablation
Description: electrophysiology substrate mapping is the critical difference between both groups.
Study NCT04719546 — intervention group
Intervention type: OTHER
Intervention: Observation of related perinatal factors
Description: Data described in Primary outcome measures will be collected in both groups
Study NCT06515275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education via video (QR code links)
Description: Video education on self-administered medications for women undergoing IVF treatment
Study NCT04753515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine combined with midazolam and remifentanil.
Description: Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.5 mcg/kg dexmedetomidine over 5 min via separate syringe pumps.
Study NCT04753515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol combined with midazolam and remifentanil.
Description: Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.33 mg/kg propoful over 5 min via separate syringe pumps.
Study NCT04556175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Health
Description: Motivational interviewing for mothers pre-and postpartum; fluoride varnish for infants/children.
Study NCT04556175 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyle
Description: Didactic maternal and child health educational sessions for mothers pre-and postpartum; fluoride varnish for infants/children.
Study NCT05556252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogenated water consumption
Description: Participants will start consuming hydrogenated water on the 16th day of the menstrual cycle and will continue to apply it until the 2nd day of the next cycle. Within the scope of the study, they will be asked to drink of 300-400 ml hydrogenated water each morning before breakfast; 300-400 ml an hour before lunch; 300-400 ml two hours after lunch; 300-400 ml an hour before dinner; 300-400 ml half an hour before going to bed. Participants will be asked to consume a minimum of 1500 ml (1.5 L) and a maximum of 2000 ml (2.0 L) hydrogenated water in total. In this way, participants will be provided with hydrogenated water for three cycles.
Study NCT05556252 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Drinking water consumption
Description: Participants will start consuming drinking water on the 16th day of the menstrual cycle and will continue to apply it until the 2nd day of the next cycle. Within the scope of the study, they will be asked to drink of 300-400 ml drinking water each morning before breakfast; 300-400 ml an hour before lunch; 300-400 ml two hours after lunch; 300-400 ml an hour before dinner; 300-400 ml half an hour before going to bed. Participants will be asked to consume a minimum of 1500 ml (1.5 L) and a maximum of 2000 ml (2.0 L) drinking water in total. In this way, participants will be provided with drinking water for three cycles.
Study NCT06284473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine is an N-methyl-D aspartate receptor agonist
Study NCT06284473 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intranasal saline flushes pollen, dust, and other debris from nasal passages. It also removes excess mucus and adds moisture
Study NCT05681988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early minimally invasive image guided endoscopic hematoma evacuation
Description: The intervention group will first receive BMT (as defined below) upon admission and early minimally invasive image guided endoscopic hematoma evacuation as an add-on therapy to BMT. Surgery will be performed within 6-24 hours after SSICH symptom onset. Surgery will be performed in an emergency operating theatre or a hybrid operation theatre equipped with intraoperative CT (in hybrid OR), neuronavigation, and neuro-endoscopy.The position and progress of the trocar towards the hematoma cavity will be monitored with neuro-navigation. The endoscope (LOTTA® system, Karl Storz Endoscopes, Germany; Minop®, BBraun, Tuttlingen, Germany or equivalent) will be inserted into the trocar and tracked using neuro-navigation. Using the pre-planned trajectory, the hematoma will be entered. Using continuous suction and irrigation, the hematoma will be aspirated and/or washed out.
Study NCT05681988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment (BMT)
Description: The control group will receive the current gold standard treatment for SSICH according to the guidelines (BMT). This involves strict blood pressure control (SBP\<140mmHg), if needed with intravenous or intraarterial blood pressure lowering agents, reversal of anticoagulation if applicable, intensive care surveillance and nursing on a ICU or stroke unit, control of seizures as well as glucose levels as needed and neurointensive monitoring if deemed necessary
Study NCT05681988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Best medical treatment (BMT)
Description: The control group will receive the current gold standard treatment for SSICH according to the guidelines (BMT). This involves strict blood pressure control (SBP\<140mmHg), if needed with intravenous or intraarterial blood pressure lowering agents, reversal of anticoagulation if applicable, intensive care surveillance and nursing on a ICU or stroke unit, control of seizures as well as glucose levels as needed and neurointensive monitoring if deemed necessary
Study NCT05347251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervicothoracic mobility program
Description: Participants in this group will receive mobilization at a cervical and thoracic level along with conventional physical therapy protocol like Hot packs and exercise therapy.~At the cervical, PA glides (central) and transverse glides will be given for mobilization.~At thoracic, PA glides (central) and transverse glides will be given for mobilization.~Exercise therapy includes stretching and strengthening both cervical and thoracic muscles. At the cervical level, neck isometric (flexion, extension, side bending) will be given to patients to enhance strengthening, and neck~stretching exercises (flexors, extensors, side benders~and rotators) will perform as well. Similarly, at the thoracic~level, strengthening and stretching of thoracic muscle will be performed
Study NCT05347251 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Treatment
Description: It will be the control group. The participants who will be allocated in this group receive the only conventional physical therapy protocol (Hot pack and exercise therapy). Exercise therapy includes stretching and strengthening of neck and upper back muscles. At the cervical level, neck isometric (flexion, extension, side bending) will be given to patients to enhance strengthening, and neck stretching exercises (flexors,~extensors, side benders, and rotators) will perform~as well. Similarly at the thoracic level, strengthening and stretching of thoracic muscle will be performed.
Study NCT04832932 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccines
Description: Emergency-use authorized COVID-19 vaccines
Study NCT04701333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline 1 MG
Description: Dopamine agonist
Study NCT04701333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05266612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG2025
Description: 1. 1.0×108PFU Day 1 and 15~2. 2.0×108PFU Day 1 and 15~3. 3.0×108PFU Day 1 and 15~4. 4.0×108PFU Day 1 and 15
Study NCT05266612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: Flat dose of 240 mg every two weeks.
Study NCT05354908 — intervention group
Intervention type: OTHER
Intervention: scientific and academic productivity
Description: Number and quartile of scientific products generated by the group
Study NCT05081531 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Adaptive Radiotherapy
Description: All the patients will be treated with VMAT technique in its RapidArc form. A simultaneous integrated boost (SIB) technique will be used. The GTV will encompass the tumor delineated on CT scan, adjusted for MRI and PET scans. Patients will be treated with a total dose of 66 Gy, 60 Gy and 54 Gy on PTV1, PTV2 and PTV3, respectively, delivered in 30 fractions, 5 fractions per week.
Study NCT06106113 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GST-HG171 Tablets
Description: 150mg GST-HG171 Tablets
Study NCT06431308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional intervention
Description: A nutrition guidance before initiation of AOM treatment include recommendations for food choices and eating habits to minimize the occurrence and severity of GI symptoms during the up-titration phase, will be given by registered dietitian (RD) from the study team. Next, each week, participants will provide weekly reports of GI symptoms occurrence and severity, by responding to queries sent via WhatsApp/SMS and for occurring symptoms, an automatically structured nutrition and behavioral treatment recommendations will be sent. Three days after each report of GI symptom(s), participants will receive an additional message and will be asked to report the occurrence and severity of the GI symptom, and their compliance with the specific dietary instructions received. If participants expressed an interest in personalized dietary guidance on this matter, the study team RD will contact him/her by telephone, within a range of 48 hours, to provide individualized recommendations
Study NCT04811131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARQ-252 cream 0.3%
Description: ARQ-252 cream 0.3%
Study NCT06461663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breast Cancer Locator Guided Breast Conserving Surgery
Description: Subjects will undergo a contrast-enhanced supine MRI and two marks will be placed on the breast. The MRI images will be transmitted to the sponsor, and the images will be used to build a BCL using 3D printing. Investigators will be provided with a 3D image of the cancer in the breast. Investigators will use a BCL (a patient-specific, plastic, bra-like form that is placed on the breast and allows the investigator to mark the edges of the tumor on the skin and to place wires inside the breast which define the center of the cancer and the tumor edges. The surgeon will then attempt to surgically remove all the tissue inside the wires used to define the tumor edges.
Study NCT04946890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX2843
Description: MRX2843 is treated at 80mg/d, 120mg/d and 180mg/d respectively
Study NCT04811131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARQ-252 Vehicle cream
Description: ARQ-252 Vehicle cream
Study NCT04811131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB phototherapy active treatment
Description: NB-UVB phototherapy active treatment
Study NCT04811131 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NB-UVB phototherapy active treatment
Description: NB-UVB phototherapy active treatment
Study NCT04811131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB phototherapy sham treatment
Description: NB-UVB phototherapy sham treatment
Study NCT05262257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Take it regularly for 12 weeks
Study NCT05262257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Take it regularly for 12 weeks
Study NCT05262257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: patients did not take any hypoglycemic drugs and adopted diet, exercise and other lifestyle intervention measures to control blood sugar.
Study NCT04811131 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NB-UVB phototherapy sham treatment
Description: NB-UVB phototherapy sham treatment
Study NCT06342908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and stool sample collection
Study NCT06342908 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Therapy
Description: Given PpDC vaccine ID
Study NCT06342908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study NCT06342908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06342908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given IM
Study NCT06155422 — intervention group
Intervention type: DRUG
Intervention: Cadonilimab
Description: recurrent or metastatic cervical cancer in the first, second or third lines Systematic treatment
Study NCT05362968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freeze-dried strawberry powder
Description: Whole strawberries are freeze-dried to form a powder with improved shelf life that will be used in this research study. Strawberry powder will be provided by the California Strawberry Commission (Watsonville, CA)
Study NCT05897008 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMAB007
Description: for subcutaneous injection only
Study NCT05897008 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xolair
Description: for subcutaneous injection only
Study NCT05251194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video laryngoscope at thyroid surgical position
Description: After induction of anesthesia and muscle relaxation, the patient will be positioned with a standard pillow to exposure neck for thyroid surgery (thyroid surgical position). Then, tracheal intubation will be performed with a McGrath video laryngoscope. During laryngoscopy with the McGrath video laryngoscope, the intubation practitioner will record the modified Cormack-Lehane grade and the percentage of glottic opening (POGO) score when it is assumed that a direct laryngoscope is used and when using the video laryngoscope, respectively.